share_log

Clene | 10-K: FY2023 Annual Report

Clene | 10-K: FY2023 Annual Report

Clene | 10-K：2023财年年报
美股SEC公告 ·  03/13 07:53
Moomoo AI 已提取核心信息
Clene Inc., a clinical-stage pharmaceutical company, reported its annual financial results, highlighting a 38% increase in total revenue from $473,000 in 2022 to $654,000 in 2023. This growth was driven by a 51% rise in product revenue and an 8% increase in royalty revenue. Despite this, the company experienced a 16% decrease in operating expenses, primarily due to reduced research and development costs, which fell from $31.92 million to $26.655 million. General and administrative expenses also decreased by 15%. However, Clene Inc. reported a net loss of $49.504 million, a 65% increase from the previous year's $29.918 million loss. The company has not yet achieved profitability and has no drugs approved for commercial sale. Clene Inc. continues to focus on developing its novel clean-surfaced nanotechnology (CSN®) therapeutics, with multiple drug assets in development and clinical trials, primarily for neurology applications. The company's future plans include initiating an international Phase 3 study of CNM-Au8 30 mg, RESTORE-ALS, in the second half of 2024, contingent upon funding, and further engagement with the FDA to support potential approval of their drug candidates.
Clene Inc., a clinical-stage pharmaceutical company, reported its annual financial results, highlighting a 38% increase in total revenue from $473,000 in 2022 to $654,000 in 2023. This growth was driven by a 51% rise in product revenue and an 8% increase in royalty revenue. Despite this, the company experienced a 16% decrease in operating expenses, primarily due to reduced research and development costs, which fell from $31.92 million to $26.655 million. General and administrative expenses also decreased by 15%. However, Clene Inc. reported a net loss of $49.504 million, a 65% increase from the previous year's $29.918 million loss. The company has not yet achieved profitability and has no drugs approved for commercial sale. Clene Inc. continues to focus on developing its novel clean-surfaced nanotechnology (CSN®) therapeutics, with multiple drug assets in development and clinical trials, primarily for neurology applications. The company's future plans include initiating an international Phase 3 study of CNM-Au8 30 mg, RESTORE-ALS, in the second half of 2024, contingent upon funding, and further engagement with the FDA to support potential approval of their drug candidates.
临床阶段药品公司Clene报告称，其年度财务业绩表现良好，总营业收入自2022年的473,000美元增长38%至2023年的654,000美元。这种增长的推动力来自产品销售收入增长51%和版税收入增长8%。尽管如此，由于研发成本降低，从3192万美元下降到2665.5万美元，公司的营业费用下降了16%。总部和行政费用也减少了15%。然而，Clene报告净亏损4950.4万美元，比前一年的2991.8万美元亏损增加了65%。该公司尚未实现盈利，并且没有获得商业销售批准的药品。Clene继续专注于开发其具有创新性的纳米技术(CSN®)治疗方案，拥有多种药品资产正在开发和进行临床试验，主要用于神经学应用。该公司未来计划包括在2024年下半年开始进行CNm-Au8 30毫克的国际3期研究RESTORE-ALS（如获得资金支持），并进一步与FDA合作支持其药品候选人的潜在批准。
临床阶段药品公司Clene报告称，其年度财务业绩表现良好，总营业收入自2022年的473,000美元增长38%至2023年的654,000美元。这种增长的推动力来自产品销售收入增长51%和版税收入增长8%。尽管如此，由于研发成本降低，从3192万美元下降到2665.5万美元，公司的营业费用下降了16%。总部和行政费用也减少了15%。然而，Clene报告净亏损4950.4万美元，比前一年的2991.8万美元亏损增加了65%。该公司尚未实现盈利，并且没有获得商业销售批准的药品。Clene继续专注于开发其具有创新性的纳米技术(CSN®)治疗方案，拥有多种药品资产正在开发和进行临床试验，主要用于神经学应用。该公司未来计划包括在2024年下半年开始进行CNm-Au8 30毫克的国际3期研究RESTORE-ALS（如获得资金支持），并进一步与FDA合作支持其药品候选人的潜在批准。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

独立文件9  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息